Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasm Metastasis 4Carcinoma 4Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Ras-mutated Metastatic Colorectal Cancer 1Osteosarcoma 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Glioma 1Glioblastoma 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Anal Cancer Metastatic 1Adenocarcinoma 1

Interventions

pembrolizumab 2Ipilimumab 2Doxorubicin 2soblidotin 1reolysin 1olaratumab 1futibatinib 1envafolimab 1brigimadlin 1belinostat 1Injections 1Immune Checkpoint Inhibitors 1Ifosfamide 1Histamine H2 Antagonists 1Gemcitabine 1Fluorouracil 1Famotidine 1Erlotinib Hydrochloride 1Docetaxel 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Histiocytoma, Malignant Fibrous × reolysin × Clear all
NCT00503295 2014-10-02

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

Oncolytics Biotech

Phase 2 Completed
53 enrolled
Sarcoma

Fibrosarcoma, Leiomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡